| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 06/08/2006 | WO2005099671A3 Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
| 06/08/2006 | WO2005092390A3 Conjugates of hydroxyalkyl starch and a protein |
| 06/08/2006 | WO2005090393A3 Multimeric protein toxins to target cells having multiple identifying characteristics |
| 06/08/2006 | WO2005072778A3 Use of amino-oxy functional groups in the preparation of vaccines conjugates |
| 06/08/2006 | US20060122374 Albumin-fused anti-angiogenesis peptides |
| 06/08/2006 | US20060122271 Stable gabapentin having pH within a controlled range |
| 06/08/2006 | US20060122259 Immobilization of taxane; anticancer, antitumor agents |
| 06/08/2006 | US20060122200 Use and application of a pharmaceutical composition containing a mixture of natural- origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm- related clinical pathologies |
| 06/08/2006 | US20060122163 adding temozolomide with dissolution enhancing agent is selected from L-histidine, L-threonine, L-asparagine, L-serine, and L-glutamine; freeze drying |
| 06/08/2006 | US20060122142 DNA vaccines for farm animals, in particular bovines and porcines |
| 06/08/2006 | US20060122137 5'-methylpyrimidine and 2'-O-methyl ribonucleotide modified double-stranded ribonucleic acid molecules |
| 06/08/2006 | US20060122124 Therapeutic agent |
| 06/08/2006 | US20060122096 Reversible modification of amine-containing compounds |
| 06/08/2006 | US20060121545 Rapamycin conjugates and antibodies |
| 06/08/2006 | US20060121519 Ligand and coordinating moiety for isolating preferential macromolecules in solution |
| 06/08/2006 | US20060121123 Forming image of sample and coated microparticle mixture by exposing to electromagnetic radiation of infrared or ultraviolet frequency; optical coherence tomography, holography, endoscopy; light, confocal, polarization, interference, and/ormulti-photon microscopy |
| 06/08/2006 | US20060121120 Sustained release ionic conjugate |
| 06/08/2006 | US20060121119 Process for producing nanoparticles of paclitaxel and albumin |
| 06/08/2006 | US20060121118 Antimycotic gel having high active compound release |
| 06/08/2006 | US20060121117 Anti-angiogenic compositions and methods of use |
| 06/08/2006 | US20060121115 Composition having gelling properties for the prolonged delivery of bioactive substances |
| 06/08/2006 | US20060121107 Agent improving proton-driven transporter-mediated absorption in digestive tract and process for producing the same |
| 06/08/2006 | US20060121103 Transdermal delivery system |
| 06/08/2006 | US20060121091 Cellular uptake of bioactive agents |
| 06/08/2006 | US20060121088 delivering to an external portion of the body passageway a therapeutic agent such as an antiangiogenic factor from a thread; treating stenosis or restenosis for example |
| 06/08/2006 | US20060121071 Stable hydroalcoholic compositions |
| 06/08/2006 | US20060121066 Sucralose formulations to mask unpleasant tastes |
| 06/08/2006 | US20060121065 Iscom preparation and use thereof |
| 06/08/2006 | US20060121062 Conjugated hydroxyalkyl starch allergen compounds |
| 06/08/2006 | US20060121056 Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics |
| 06/08/2006 | US20060121019 Compositions for treating cystic fibrosis |
| 06/08/2006 | US20060121015 Probiotic bifidobacterium strains |
| 06/08/2006 | US20060121012 An implantable device coated with a matrix-bound ligand that binds the cell membrane markers of genetically altered mammalian cells and express and secrete at least one therapeutic gene product; vascular diseases; anticarcinogenic agents |
| 06/08/2006 | US20060120999 Protein and peptide expression for passive immunity |
| 06/08/2006 | US20060120992 Rapid dehydration of proteins |
| 06/08/2006 | US20060120977 Controlled delivery system of antifungal and keratolytic agents for local treatment of fungal infections of the nail and surrounding tissues |
| 06/08/2006 | US20060120974 Nicotine delivery systems |
| 06/08/2006 | US20060120973 powders containing human growth hormone; for treatment or prevention of growth retardation, growth hormone deficiency, or for control of HIV-related wasting and cachexia |
| 06/08/2006 | US20060120964 Inorganic reaction product of metal oxides, metal sulfides |
| 06/08/2006 | US20060120959 Method for the selective and quantitative functionalization of immunoglobulin fab fragments, conjugate compounds obtained with the same and compositions thereof |
| 06/08/2006 | US20060118000 Water dispersible compositions containing natural hydrophilic water-insoluble pigments, methods of preparing same and their use |
| 06/08/2006 | DE102004058071A1 Verfahren zur Reinigung von polaren Vinylverbindungen A process for the purification of the polar vinyl compounds |
| 06/08/2006 | DE102004028629A1 Stabilisierung von Farbstoffen in kosmetischen und dermatologischen Zubereitungen Stabilization of dyes in cosmetic and dermatological preparations |
| 06/08/2006 | DE102004028018A1 Verwendung von Stoffen, die Terpene und/oder Duftstoffalkohole freisetzen, zur Hemmung der Adhäsion von Mikroorganismen Use of substances which release terpenes and / or perfume alcohols to inhibit the adhesion of microorganisms |
| 06/08/2006 | CA2589802A1 Plad domain peptides with increased serum half life due to conjugation to domain antibodies |
| 06/08/2006 | CA2589800A1 Bispecific domain antibodies targeting serum albumin and glp-1 or pyy |
| 06/08/2006 | CA2589484A1 Methods of using temozolomide formulation intrathecally in the treatment of cancers |
| 06/08/2006 | CA2589397A1 Viscoelastic solutions containing sodium hyaluronate and hydroxypropyl methyl cellulose, preparation and uses |
| 06/08/2006 | CA2588892A1 Anti-il-1r1 single domain antibodies and therapeutic uses |
| 06/08/2006 | CA2586807A1 Topical nepafenac formulations |
| 06/08/2006 | CA2586323A1 Aqueous dispersions of a mixture of only slightly water soluble or water insoluble active substances and a single-celled protein material |
| 06/08/2006 | CA2575924A1 Toxin compounds with enhanced membrane translocation characteristics |
| 06/07/2006 | EP1666585A1 Macroencapsulated secretory cells |
| 06/07/2006 | EP1666503A1 Polysaccharide pseudo-sponge |
| 06/07/2006 | EP1666496A1 Interferon-beta composite |
| 06/07/2006 | EP1666486A1 Compound modified with glycerol derivative |
| 06/07/2006 | EP1666069A1 Paclitaxel aqueous injection solution and methods for preparing the same |
| 06/07/2006 | EP1666052A1 Uses of agonists and antagonists to modulate activity of TNF-related molecules |
| 06/07/2006 | EP1666047A1 Pharmaceutical compositions comprising nitric oxide-releasing pyrrolidones |
| 06/07/2006 | EP1666045A1 Sphingomyelin containing preparation for the enhancement of tumor therapy and for the treatment of rheumatoid arthritis |
| 06/07/2006 | EP1666043A1 Product containing prostaglandin |
| 06/07/2006 | EP1666039A1 Use of L-alpha-lysophosphatidylcholine inhibitors to prevent inflammation |
| 06/07/2006 | EP1666032A1 Lowly irritative adhesive patch |
| 06/07/2006 | EP1666030A1 Improved nicotine lozenge and therapeutic method for smoking cessation |
| 06/07/2006 | EP1666029A1 Pressurised metered dose inhalers (MDI) |
| 06/07/2006 | EP1666028A1 Dry powder compositions having improved dispersivity |
| 06/07/2006 | EP1666026A2 Non-aqueous single phase biocompatible viscous vehicles and methods for preparing the same |
| 06/07/2006 | EP1666025A1 DRUG DELIVERY SYSTEM FOR SUB-TENON’S CAPSULE ADMINISTRATION OF FINE GRAINS |
| 06/07/2006 | EP1666024A1 Preparation for rectal administration |
| 06/07/2006 | EP1666020A1 Compositions for the preparation of carbon dioxide gel for external use and carbon dioxide gels for external use |
| 06/07/2006 | EP1664321A2 Methods for expression and purification of immunotoxins |
| 06/07/2006 | EP1664319A2 Process for producing a capsular polysaccharide for use in conjugate vaccines |
| 06/07/2006 | EP1664316A1 Polyethyleneglycol-modified lipid compounds and uses thereof |
| 06/07/2006 | EP1664297A2 Nanoparticles for delivery of nucleic acids and stable double-stranded rna |
| 06/07/2006 | EP1664270A1 Chimeric antigens for breaking host tolerance to foreign antigens |
| 06/07/2006 | EP1664117A2 Immunogen |
| 06/07/2006 | EP1664116A2 Improved antibodies having altered effector function and methods for making the same |
| 06/07/2006 | EP1664069A1 Mitoquinone derivatives used as mitochondrially targeted antioxidants |
| 06/07/2006 | EP1664044A1 S-tenatoprazole sodium monohydrate salt and the use thereof in the form of a proton pump inhibitor |
| 06/07/2006 | EP1663933A2 Improved delivery by labile hydrophobic modification of drugs |
| 06/07/2006 | EP1663397A1 Injectable therapeutic formulations |
| 06/07/2006 | EP1663316A2 Nucleic acid lipophilic conjugates |
| 06/07/2006 | EP1663315A2 Targeted lipid-drug formulations for delivery of drugs to myeloid and lymphoid immune cells |
| 06/07/2006 | EP1663314A2 Pharmaceutical products comprising bisphosphonates |
| 06/07/2006 | EP1663306A2 Antibodies with altered effector functions |
| 06/07/2006 | EP1663296A1 Liquid human growth hormone formulation containing polyethylene glycol |
| 06/07/2006 | EP1663295A2 Stable formulations of peptides |
| 06/07/2006 | EP1663292A1 Formulation of albumin-free erythropoietin |
| 06/07/2006 | EP1663286A2 In vivo modulation of neuronal transport |
| 06/07/2006 | EP1663284A1 Compositions and methods for treatment of psoriasis |
| 06/07/2006 | EP1663281A2 Poly-pegylated protease inhibitors |
| 06/07/2006 | EP1663279A2 Modified protease inhibitors |
| 06/07/2006 | EP1663209A1 Novel orally administered dosage form for 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-ethyl proprionate and salts thereof |
| 06/07/2006 | EP1663186A2 Stable pharmaceutical composition of fluoroether compound for anesthetic use, method for stabilizing a fluoroether compound, use of stabilizer agent for precluding the degradation of a fluoroether compound |
| 06/07/2006 | EP1663181A2 Protein binding compounds |
| 06/07/2006 | EP1663178A1 Films based on poly(ethylene oxide), and drug delivery systems made thereof |
| 06/07/2006 | EP1663177A1 Topical preparations comprising a hydrophilic carrier and a silicone matrix |
| 06/07/2006 | EP1663165A2 Improved stearate composition and method of production thereof |
| 06/07/2006 | EP1663158A2 Specific delivery of drugs to the brain |
| 06/07/2006 | EP1663147A1 Formulations of anthraquinone derivatives |